What AMF Medical does

AMF Medical is a Swiss medical device company that developed an insulin patch pump for diabetes management. Founded in 2014 and headquartered at the EPFL Innovation Park in St-Sulpice, Switzerland, the company operated with a small team (1-10 employees) focused on miniaturized insulin delivery technology. The product, referred to generically as an "insulin patch pump," was positioned to address unmet needs in convenient insulin administration for diabetes patients; however, no commercial product name, technical specifications, or pricing details were publicly disclosed prior to acquisition.

The company's go-to-market strategy and revenue model were never independently commercialized. AMF Medical sustained operations through a series of dilutive and non-dilutive funding rounds totaling approximately $20.9 million between 2014 and 2022, including grants from Swiss government bodies (SPEI), European innovation programs (EISMEA, Innosuisse), and acceleration programs (MassChallenge, FIT Foundation). Its products and services were distributed as part of Tandem Diabetes Care's portfolio following acquisition.

On January 23, 2023, Tandem Diabetes Care (NASDAQ: TNDM) completed the acquisition of AMF Medical, integrating its patch pump technology and IP into Tandem's broader diabetes technology portfolio, which includes the t:slim X2 insulin pump. Following the acquisition, AMF Medical ceased to operate as an independent entity and now functions as a wholly-owned subsidiary within Tandem's Swiss operations, branded as "Tandem Switzerland."

Name

AMF Medical

Legal name

AMF Medical

Website

https://sigipump.com

Company type

Private

Founded year

2014

Operating status

Acquired

Headcount range

1–10 employees

Short description

AMF Medical was a Swiss MedTech company developing a proprietary insulin patch pump for diabetes management. Acquired by Tandem Diabetes Care in January 2023, it now operates as Tandem Switzerland within the parent's diabetes technology portfolio.

Ownership category

akta.pro rank

Product category

Insulin Delivery Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)

akta.pro secondary industry

Insulin Pumps & Patch Pumps (HLAHAIAG)

Keywords

• Insulin patch pump
• Diabetes management
• Insulin delivery devices
• Continuous subcutaneous infusion
• Wearable medical devices

Headquarters

HQ city

Ecublens

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Core offering

AMF Medical developed a proprietary insulin patch pump, a miniaturized wearable medical device designed to deliver continuous subcutaneous insulin for diabetes management. The technology was developed in Switzerland and integrated into Tandem Diabetes Care's portfolio of insulin delivery solutions following the January 2023 acquisition.

Product overview

AMF Medical was a medical device company that developed an insulin patch pump. The company was acquired by Tandem Diabetes Care on January 23, 2023, and now operates as part of Tandem Diabetes Care, Inc. (NASDAQ:TNDM). Based in Switzerland at EPFL Innovation Park in St-Sulpice, AMF Medical's patch pump technology was incorporated into Tandem's portfolio of insulin delivery solutions including the t:slim X2 insulin pump.

Differentiator

Problem solved

Functional benefit

Products and services

• Insulin Patch Pump Proprietary miniaturized, wearable patch pump designed for continuous subcutaneous insulin delivery in diabetes management, eliminating the tubing of conventional pumps. Targeted at insulin-dependent diabetes patients seeking discreet and convenient insulin therapy.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Tandem Diabetes CarecoreStrategic or Co-development Partner · 23 January 2023AMF Medical was acquired by Tandem Diabetes Care (NASDAQ: TNDM) on January 23, 2023. AMF Medical is now part of Tandem Diabetes Care, a global insulin delivery and diabetes technology company. The acquisition integrates AMF Medical's insulin patch pump technology into Tandem's diabetes management portfolio.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• EOFlow: EOFlow developed the EOPatch, a tubeless disposable insulin patch pump directly competing with Omnipod and AMF's Sigi Pump in form factor and target use case (basal/bolus insulin delivery).
• Insulet Corporation: Insulet is the global leader in tubeless insulin patch pumps (Omnipod). Most directly comparable to AMF Medical's Sigi Pump in product category, target customers (insulin-dependent diabetes patients), and wearable form factor.
• Tandem Diabetes Care: Tandem acquired AMF Medical in January 2023 and is now its parent company. Tandem's t:slim X2 and upcoming t:slim X3 tubed pumps, combined with Control-IQ AID software, make it the closest comparator in insulin delivery technology and target market.
• Ypsomed: Swiss-headquartered developer of the mylife YpsoPump and the upcoming tubeless YpsoPump Patch. Directly comparable in product (insulin patch pump), geography (Switzerland/Europe), and customer segment (insulin-dependent patients).

Broad incumbents

• Medtronic Diabetes: Medtronic's MiniMed 780G AID system is a broad incumbent in insulin delivery with both tubed pumps and a hybrid closed-loop ecosystem. Comparable as a large, established competitor in the same end market for insulin pump therapy.
• Roche Diabetes Care: Roche offers the Accu-Chek Insight and Solo tubeless patch pump in select markets. Comparable as a diversified diabetes-care incumbent overlapping with AMF's insulin delivery and glucose management offerings.

Emerging players

• Debiotech: Swiss-based MedTech developing miniaturized drug delivery patch pumps including insulin applications. Comparable as a small, Swiss-originated player focused on wearable patch-pump technology for chronic disease management.
• Diabeloop: European AID/closed-loop developer partnering with pump manufacturers to integrate its algorithm. Adjacent comparable in the integrated AID ecosystem that AMF's pump would plug into via Tandem.
• PharmaSens: Swiss-based developer of the InsuPatch and upcoming niia essential/nia long insulin patch pumps. Closely comparable as a small European patch-pump specialist targeting the same wearable insulin-delivery niche.

Others

• Dexcom: Leading CGM manufacturer whose sensors integrate with Tandem's pumps. Comparable as a complementary technology provider in the same insulin-delivery/diabetes-management value chain rather than a direct pump competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key highlights6 records

Customer concentration

• Xx.com/TandemDiabetes
• Facebookfacebook.com/TandemDiabetes
• LinkedInlinkedin.com/company/amf-medical-sa

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMF Medical